Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/09/01, \ 11/o3/02, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

ABN		
92 00	9 657 489	
We (t	the entity) give ASX the following	information.
	1 – All issues ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Performance Rights (vesting 1 July 2019)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	23,310

Name of entity
ALS Limited

Appendix 3B Page 1 04/03/2013

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Performance Rights are granted to senior executives and key personnel pursuant to the ALS Long Term Incentive (Equity) Plan, adopted at the AGM.

Each Performance Right carries a right to one fully paid ordinary share in ALS upon specific results being achieved over a three-year period.

The Performance Rights are subject to combined EPS (earnings per share), TSR (total shareholder return), EBITDA margin (earnings before interest, tax, depreciation and amortisation) and ROCE (return on capital employed) measurements.

The performance period for this tranche of Performance Rights is measured from 1 April 2016 to 31 March 2019.

Vesting of the Performance Rights will be calculated on 1 July 2019.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

The ordinary shares to be allotted on the exercise of the Performance Rights after specific performance results being achieved, will rank equally with all existing fully paid ordinary shares in ALS Limited from the date of allotment.

\$4.29 per Performance Right granted.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Performance Rights are granted as equity compensation benefits to senior executives and key personnel in accordance with the ALS Long Term Incentive (Equity) Plan.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	N/A.
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A.
6c	Number of *securities issued without security holder approval under rule 7.1	N/A.
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A.
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A.
6f	Number of *securities issued under an exception in rule 7.2	N/A.
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A.

Appendix 3B Page 3 04/03/2013

⁺ See chapter 19 for defined terms.

6h If *securities were issued under 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

N/A. Annexure 1 is not required and has been omitted.

+Class

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

21 September 2016.

Number

- 8 Number and +class of all ⁺securities quoted on ASX (including the +securities in section 2 if applicable)
- Number and +class of all 9 *securities not quoted on ASX (including the +securities in section 2 if applicable)

504,221,143	Ordinary shares.
Number	+Class
345,848	Performance Rights (vesting 1 July 2017)
55,866	Share Rights (vesting 1 July 2017)
545,080	Performance Rights (vesting 1 July 2018)
48,062	Share Rights (vesting 1 July 2018)
135,514	Share Rights (vesting 1 November 2018)
10,000	Share Rights (vesting 1 December 2018)
982,390	Performance Rights (vesting 1 July 2019)

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Performance Rights and Share Rights do not carry a right to a dividend until vested and exercised into Ordinary shares.

Part 2 – Pro rata issue N/A

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
	_	
15	⁺ Record date to determine entitlements	
16	Will holdings on different	
10	registers (or subregisters) be aggregated for calculating	
	entitlements?	
	-	
17	Policy for deciding entitlements in relation to fractions	
	L	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
	_	
21	Amount of any underwriting fee or commission	
	_	
22	Names of any brokers to the issue	

Appendix 3B Page 5 04/03/2013

⁺ See chapter 19 for defined terms.

23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	

Part 3 – Quotation of securities N/A

You need only complete this section if you are applying for quotation of securities

Type of *securities (*tick one*)

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

(a)		*Securities described in Part 1	
(b)		All other ⁺ securities	
			l of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that	have ticked box 34(a)	
Addi	tional s	securities forming a new c	lass of securities
		e you are providing the information	on or
docur 35	nents N/A		recurities, the names of the 20 largest holders of the 10 number and percentage of additional +securities
36	N/A	If the *securities are *equity	securities, a distribution schedule of the additional mber of holders in the categories
37	N/A	A copy of any trust deed for t	he additional ⁺ securities
Entiti	es that	have ticked box 34(b)	
38		ber of *securities for which tation is sought	
39		s of ⁺ securities for which ation is sought	
40	all rewith *secu If the rank • th	ne *securities rank equally in espects from the *issue date an existing *class of quoted arities? additional *securities do not equally, please state: the date from which they do the extent to which they	
	pa di di pa • th ra re	nrticipate for the next vidend, (in the case of a trust, stribution) or interest ayment he extent to which they do not not equally, other than in lation to the next dividend, stribution or interest ayment	

Appendix 3B Page 7 04/03/2013

⁺ See chapter 19 for defined terms.

Reason for request for quotation now	1
Example: In the case of restricted securities, en of restriction period	d
(if issued upon conversion of another ⁺ security, clearly identife that other ⁺ security)	

Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

Number	+Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22 September 2016 (Company secretary)

Print name: Tim Mullen

== == == ==